These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 37705525)

  • 21. Flow cytometric aberrancies in plasma cell myeloma and MGUS - correlation with laboratory parameters.
    Gupta S; Karandikar NJ; Ginader T; Bellizzi AM; Holman CJ
    Cytometry B Clin Cytom; 2018 May; 94(3):500-508. PubMed ID: 29316245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Utility and feasibility of a six-color multiparametric flow cytometry for measurable residual disease analysis in plasma cell myeloma in resource-limited settings with 5-year survival data.
    Sharma P; Singh Sachdeva MU; Varma N; Bose P; Aggarwal R; Malhotra P
    J Cancer Res Ther; 2021; 17(6):1515-1520. PubMed ID: 34916387
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential therapeutic biomarkers in plasma cell myeloma: a flow cytometry study.
    Zheng W; Liu D; Fan X; Powers L; Goswami M; Hu Y; Lin P; Medeiros LJ; Wang SA
    Cytometry B Clin Cytom; 2013; 84(4):222-8. PubMed ID: 23450831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of CD19 and CD27 in the diagnosis of multiple myeloma by flow cytometry: a new statistical model.
    Cannizzo E; Carulli G; Del Vecchio L; Ottaviano V; Bellio E; Zenari E; Azzarà A; Petrini M; Preffer F
    Am J Clin Pathol; 2012 Mar; 137(3):377-86. PubMed ID: 22338049
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD24 Is a Prognostic Marker for Multiple Myeloma Progression and Survival.
    Gross Even-Zohar N; Pick M; Hofstetter L; Shaulov A; Nachmias B; Lebel E; Gatt ME
    J Clin Med; 2022 May; 11(10):. PubMed ID: 35629039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [The characteristics of 62 cases of CD20-positive multiple myeloma].
    Li Z; Xu Y; An G; Wang H; Deng S; Zhao Y; Qiu L
    Zhonghua Xue Ye Xue Za Zhi; 2015 Jan; 36(1):44-8. PubMed ID: 25641146
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Influence of CD117 Expression on Response of Multiple Myeloma Patients to Chemotherapy].
    Tang HL; Shu MM; Dong BX; Gu HT; Liang R; Bai QX; Yang L; Zhang T; Gao GX; Chen XQ
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1346-51. PubMed ID: 26524035
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimal residual disease detection in multiple myeloma: comparison between BML single-tube 10-color multiparameter flow cytometry and EuroFlow multiparameter flow cytometry.
    Sato K; Okazuka K; Ishida T; Sakamoto J; Kaneko S; Nashimoto J; Uto Y; Ogura M; Yoshiki Y; Abe Y; Maeda A; Hamazaki H; Tsukada N; Hiragohri Y; Suzuki K
    Ann Hematol; 2021 Dec; 100(12):2989-2995. PubMed ID: 34430990
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Comparison and analysis of minimal residual disease in multiple myeloma patients detected by 4-color and 8-color fluorescence antibody panels].
    Wang YZ; Lu J; Hao L; Chang Y; He LL; Huang XJ; Liu YR
    Zhonghua Xue Ye Xue Za Zhi; 2017 Apr; 38(4):272-278. PubMed ID: 28468086
    [No Abstract]   [Full Text] [Related]  

  • 30. Immunophenotypic heterogeneity of normal plasma cells: comparison with minimal residual plasma cell myeloma.
    Liu D; Lin P; Hu Y; Zhou Y; Tang G; Powers L; Medeiros LJ; Jorgensen JL; Wang SA
    J Clin Pathol; 2012 Sep; 65(9):823-9. PubMed ID: 22685235
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunophenotypic Heterogeneity of Polytypic Plasma Cells and the Impact on Myeloma Minimal Residual Disease Detection by Multiparameter Flow Cytometry.
    Schouweiler KE; Karandikar NJ; Holman CJ
    Cytometry B Clin Cytom; 2019 Jul; 96(4):310-318. PubMed ID: 31140731
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Correlation between Expression of CD200 and Regulatory T Cells in Multiple Myeloma and Its Significance in Prognostic Stratification].
    Zhu MX; Wan WL; Li HS; Wang YF; Wang J; Ling HS; Yan XX; Ke XY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Oct; 24(5):1427-1432. PubMed ID: 27784369
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Malignant plasmacytes in bone marrow detected by flow cytometry as a predictor for the risk stratification system of multiple myeloma.
    Tian M; Liu Z; Han M; Liu H; Xiang C; Mi F; Deng L; Meng N; Fu R
    Cytometry B Clin Cytom; 2022 Jan; 102(1):44-49. PubMed ID: 34057806
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ten Color Multiparameter Flow Cytometry in Bone Marrow and Apheresis Products for Assessment and Outcome Prediction in Multiple Myeloma Patients.
    Riebl V; Dold SM; Wider D; Follo M; Ihorst G; Waldschmidt JM; Jung J; Rassner M; Greil C; Wäsch R; Engelhardt M
    Front Oncol; 2021; 11():708231. PubMed ID: 34485145
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Understanding the Bioactivity and Prognostic Implication of Commonly Used Surface Antigens in Multiple Myeloma.
    Lebel E; Nachmias B; Pick M; Gross Even-Zohar N; Gatt ME
    J Clin Med; 2022 Mar; 11(7):. PubMed ID: 35407416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antigen Expression Patterns of Plasma Cell Myeloma: An Association of Cytogenetic Abnormality and International Staging System (ISS) for Myeloma.
    Shin SY; Lee ST; Kim HJ; Kim SJ; Kim K; Kang ES; Kim SH
    J Clin Lab Anal; 2015 Nov; 29(6):505-10. PubMed ID: 25277787
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inability of a monoclonal anti-light chain antibody to detect clonal plasma cells in a patient with multiple myeloma by multicolor flow cytometry.
    van Velzen JF; van den Blink D; Bloem AC
    Cytometry B Clin Cytom; 2013; 84(1):30-2. PubMed ID: 23019187
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Old and new immunophenotypic markers in multiple myeloma for discrimination of responding and relapsing patients: The importance of "normal" residual plasma cell analysis.
    Pojero F; Casuccio A; Parrino MF; Cardinale G; Colonna Romano G; Caruso C; Gervasi F
    Cytometry B Clin Cytom; 2015; 88(3):165-82. PubMed ID: 25529228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multiple Myeloma Immunophenotype Related to Chromosomal Abnormalities Used in Risk Assessment.
    Radzevičius M; Dirsė V; Klimienė I; Matuzevičienė R; Kučinskienė ZA; Pečeliūnas V
    Diagnostics (Basel); 2022 Aug; 12(9):. PubMed ID: 36140450
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Analysis of immunophenotype and leukemia associated immunophenotype in 610 patients with acute myeloid leukemia].
    Liu YR; Wang YZ; Chen SS; Chang Y; Fu JY; Li LD; Wang H; Yu H; Jiang B; Huang XJ
    Zhonghua Xue Ye Xue Za Zhi; 2007 Nov; 28(11):731-6. PubMed ID: 18457262
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.